Efgartigimod following plasma exchange in the treatment of subjects with generalised myasthenia gravis: study protocol for a multicentre, three-arm, open-label study.

ABSTRACT:

Introduction

Myasthenia gravis (MG), an IgG-mediated autoimmune disorder targeting neuromuscular junctions, shows refractory in 12-20% of generalised MG (gMG) patients despite immunotherapies. Plasma exchange (PLEX) transiently depletes pathogenic mediators, while neonatal Fc receptor antagonists (eg, efgartigimod) offer novel therapeutic potential. Both PLEX and efgartigimod require adjunctive non-steroidal immunosuppressive therapy (NSIST) for sustained remission. This study aims to evaluate the effectiveness and safety of efgartigimod working as a bridge treatment after PLEX but before NSIST taking effect, while concurrently conducting a comparative analysis of clinical outcomes between PLEX and efgartigimod in gMG.

Methods and analysis

This multicentre, open-label, three

SUBMITTER: Wang K 

PROVIDER: S-EPMC12320067 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature